Our Portfolio

ASX-100 neutrophil targeting platform to treat significant unmet medical needs
PI: Dr. Lola Eniola-Adefeso, University of Michigan
Visit site

Targeted therapeutics platform for Infectious diseases
PI: Dr. Philip Low, Purdue University

Single molecule protein sequencing
PI: Dr. Edward Marcotte, University of Texas at Austin
Visit site

Hyper-targeted small molecules for reprogramming immune cells to treat disease
PI: Dr. Philip Low, Purdue University
Visit site

Fracture targeting therapeutic for bone healing
PI: Dr. Philip Low, Purdue University
Visit site

Immunoproteasome modulating therapeutics to transform treatment of autoimmune and inflammatory diseases.
PI: Gang Lin, Ph.D. and Carl Nathan, M.D. of Weill Cornell Medicine